[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Ozmosi [@OzmosiHealth](/creator/twitter/OzmosiHealth) on x 2633 followers Created: 2023-10-13 20:35:34 UTC Pharma/Biotech Highlights: $CBIO: FDA accepts Catalyst Pharma's S-NDA, advancing FIRDAPSEĀ®. $ARDX: Ardelyx presents XPHOZAH data at Kidney Week. $THTX: Study reports findings on Trogarzo administration. $LBTSF: Almirall's Lebrikizumab aids dermatitis patients.  XXXXX engagements  **Related Topics** [$lbtsf](/topic/$lbtsf) [$thtx](/topic/$thtx) [$ardx](/topic/$ardx) [$cbio](/topic/$cbio) [Post Link](https://x.com/OzmosiHealth/status/1712930096711979428)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Ozmosi @OzmosiHealth on x 2633 followers
Created: 2023-10-13 20:35:34 UTC
Pharma/Biotech Highlights:
$CBIO: FDA accepts Catalyst Pharma's S-NDA, advancing FIRDAPSEĀ®. $ARDX: Ardelyx presents XPHOZAH data at Kidney Week. $THTX: Study reports findings on Trogarzo administration. $LBTSF: Almirall's Lebrikizumab aids dermatitis patients.
XXXXX engagements
/post/tweet::1712930096711979428